Engineered TFH-Like Cells Enhance Anti-Tumor Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The molecular features of tumor-infiltrating CD4+ T cells that provide 'help' for generating robust anti-tumor CD8+ T cell effector and tissue resident memory responses are not fully understood, limiting the development of effective immunotherapy strategies.
Innovation Solution
Integrated weighted correlation network analysis (iWGCNA) and single-cell transcriptomic analysis reveal that follicular helper T cell (TFH) programs in tumor-infiltrating CD4+ T cells are associated with CD8+ T cell proliferation and cytotoxicity, leading to the engineering of TFH-like cells with modulated expression of surface markers such as CD4, CXCL13, and CXCR5 to enhance anti-tumor immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunotherapy approaches are used to activate CD8+ T cells, then some anti-tumor immune response is generated, but the response is insufficient in most patients due to lack of understanding of CD4+ T cell help mechanisms
Solution Approach 1:
The patent uses integrated weighted correlation network analysis (iWGCNA) to establish feedback loops between CD4+ T cell transcriptional programs and CD8+ T cell functional outcomes. By identifying that TFH programs in CD4+ T cells correlate with CD8+ T cell proliferation and cytotoxicity, the system creates a feedback mechanism where CD4+ T cell molecular profiles inform and improve CD8+ T cell activation strategies, thereby enhancing overall immunotherapy reliability.
Solution Approach 2:
The patent identifies CD4+ T cells, specifically those with TFH programs, as intermediary elements that mediate between the immunotherapy intervention and the ultimate anti-tumor effect. These CD4+ T cells act as intermediaries that provide essential help signals to CD8+ T cells through direct cell-cell contact and cytokine secretion, bridging the gap between therapeutic administration and effective tumor killing.
2Measurement precision
If single-cell transcriptomic analysis is performed to identify TFH-like cells, then molecular identity and functionality are revealed, but the complexity of analysis and cell characterization increases
Solution Approach 1:
The patent segments the complex immune cell population into distinct functional subsets based on transcriptional profiles. By using single-cell RNA sequencing to identify specific CD4+ T cell subsets with TFH programs (characterized by genes like BCL6, CXCL13, and PD-1), the system divides the heterogeneous cell population into manageable, functionally-defined groups. This segmentation allows precise characterization of TFH-like cells without being overwhelmed by overall population complexity.
Solution Approach 2:
The patent changes the analytical parameters from bulk tissue analysis to single-cell transcriptomic parameters. By measuring gene expression at the single-cell level rather than averaging across populations, the system detects subtle transcriptional differences that define TFH-like cell functionality. This parameter change enables precise identification of cells expressing specific combinations of markers (CXCL13+, PD-1+, BCL6+) that would be invisible in bulk analysis.
Data Source
AI summary
Disclosed herein are isolated follicular helper T cell (TFH) and engineered follicular helper T cell (TFH) and methods of isolating or engineering such cells. Further disclosed herein are methods of using such cells for treating diseases, such as cancer.